Summary：**Surprising Study Shows Common Knee Surgery No Better Than Placebo***Introduction* A new multicent

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Surprising Study Shows Common Knee Surgery No Better Than Placebo**

*Introduction*
A new multicenter trial has cast fresh doubt on one of orthopedics’ most frequently performed operations. Researchers found that arthroscopic partial meniscectomy (APM)—the procedure that trims torn knee cartilage—did not improve pain or function any more than a sham surgery. The results, published in *The Lancet Orthopaedics*, add to a growing body of evidence questioning the value of a surgery that accounts for roughly 750,000 procedures each year in the United States alone.

*Key Developments*
The study enrolled 240 patients aged 35–65 with symptomatic medial meniscus tears confirmed by MRI. Participants were randomly assigned to either genuine APM or a placebo procedure in which surgeons made skin incisions and manipulated the joint without touching the meniscus. Both groups received identical postoperative rehabilitation. After 12 months, pain scores on the Visual Analog Scale improved by an average of 1.2 points in the surgery group and 1.0 points in the placebo group—a difference that fell short of the pre‑specified clinically important threshold. Secondary outcomes, including knee‑specific quality‑of‑life scores and return‑to‑activity rates, showed no statistically significant advantage for the operative arm. Notably, adverse event rates were low and comparable across groups, suggesting that the procedure’s risks—notably infection and postoperative stiffness—are not offset by measurable benefit.

*Industry Analysis*
Orthopedic device manufacturers and surgery centers have long marketed APM as a minimally invasive solution for mechanical knee symptoms. The latest data challenge that narrative, echoing earlier sham‑controlled trials from Finland (2013) and the United States (2020) that reported similar null findings. Health economists point out that, with an average cost of $4,000–$6,000 per case, the procedure contributes billions to annual healthcare spending without clear patient benefit. Some insurers have begun tightening prior‑authorization criteria, while professional societies are revising guidelines to emphasize conservative management—physical therapy, weight control, and activity modification—as first‑line treatment for degenerative meniscal lesions.

*Future Outlook*
The accumulating placebo‑controlled evidence is likely to accelerate a shift toward non‑operative pathways. Researchers are now exploring whether targeted biologic injections